Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIR101 in Hematologic Malignancy Post-Haploidentical HSCT
NCT01794299Phase 2Completed
- Sponsor
- Kiadis Pharma
- Start
- Mar 2013
- Primary completion
- Jun 2016
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 4
01
Overview
A Phase 2 trial of ATIR101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by Kiadis Pharma. Started Mar 2013; status: completed.
02
Drugs
ATIR101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01794299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01794299.